In a report published Tuesday, Jefferies analyst Corey Davis reiterated a Hold rating on Actavis ACT, and raised the price target from $120.00 to $133.00.
In the report, Davis noted, “ACT buying WCRX makes sense strategically and financially, but given the stock run subsequent to a formal announcement, ACT looks fairly valued based on our new numbers. We estimate '14 pro forma EPS of $13.27 (implying 47% accretion) but given WCRX's anticipated revenue cliff in '15/'16, buying slower growth/generic risk warrants use of a lower 10x multiple (prior 13x on ACT standalone) on combined EPS and thus we maintain our Hold.”
Actavis closed on Monday at $125.50.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in